nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

22.07.2023 | Research

Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy

verfasst von: Gregory P. Swanson, Kendall Hammonds, Sameer Jhavar

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 14/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

In men with biochemical recurrence (BCR) of prostate cancer (PCA) after radical prostatectomy (RP), there is limited data on the effectiveness of adding elective pelvic nodal radiation (EPNI) to salvage prostate bed radiation (PBRT) without androgen deprivation therapy (ADT) to prevent progression.

Materials and methods

Retrospective chart review of 326 patients treated for BCR of PCA from a single institution was performed to capture baseline pre-operative PSA, pathologic details, post-operative PSA, treatment details (radiation and ADT), subsequent failure (rising PSA), response to radiation, and subsequent outcomes after radiation.

Results

Between 2004 through 2017, 326 patients received PBRT. Majority (n = 253; 78%) did not receive ADT. Majority received EPNI (n = 227; 90%) with salvage PBRT (n = 213; 94%). The median pre-PBRT PSA was 0.50 ng/ml (0.10–75.60 ng/ml). Of the patients that did not receive ADT, 83% (210/253) achieved an undetectable (< 0.2 ng/ml) PSA after salvage PBRT. After a median follow-up of 87 months, 172 (53%) patients were without a rising PSA and 50 (15%) developed metastatic disease.

Conclusion

Outcomes with salvage PBRT plus EPNI without ADT appear comparable to salvage PBRT plus EPNI plus ADT. These results need confirmation in a randomized setting.

Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D et al (2022) A comprehensive assessment of ⁶⁸Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. J Nucl Med 63:567–572. https://doi.org/10.2967/jnumed.121.262412CrossRefPubMedPubMedCentral

Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T (2016) The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiother Oncol 118(1):131–135. https://doi.org/10.1016/j.radonc.2015.10.028. (Epub 2015 Nov 30 PMID: 26653358)CrossRefPubMed

Böhmer D, Siegmann A, Scharl S, Ruf C, Wiegel T, Krafcsik M et al (2022) Impact of dose escalation on the efficacy of salvage radiotherapy for recurrent prostate cancer—a risk-adjusted, matched-pair analysis. Cancers (Basel) 14:1320. https://doi.org/10.3390/cancers14051320CrossRefPubMed

Burdett S, Fisher D, Parker CC, Sydes MR, Pommier P, Sargos P et al (2022) LBA64 duration of androgen suppression with post-operative radiotherapy (DADSPORT): a collaborative meta-analysis of aggregate data. Ann Oncol 33(7):S1428–S1429. https://doi.org/10.1016/j.annonc.2022.08.067CrossRef

Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL et al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20:1740–1749. https://doi.org/10.1016/S1470-2045(19)30486-3CrossRefPubMed

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P et al (2021) Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. Eur Urol 80:306–315CrossRefPubMed

Jensen GL, Jhavar SG, Ha CS, Hammonds KP, Swanson GP (2022) The cost of elective nodal coverage in prostate cancer: late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis. Clin Transl Radiat Oncol 36:63–69. https://doi.org/10.1016/j.ctro.2022.06.008CrossRefPubMedPubMedCentral

King CR (2016) The dose–response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 121:199–203. https://doi.org/10.1016/j.radonc.2016.10.026. (Epub 2016 Nov 15)CrossRefPubMed

Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 21(10):1331–1340. https://doi.org/10.1016/S1470-2045(20)30456-3. (PMID: 33002437)CrossRefPubMed

Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39:1234–1242. https://doi.org/10.1200/JCO.20.03282CrossRefPubMed

Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396(10260):1413–1421. https://doi.org/10.1016/S0140-6736(20)31553-1. (Epub 2020 Sep 28 PMID: 33002429)CrossRefPubMed

Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H et al (2022) LBA9 duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol 33(7):S1427CrossRef

Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA et al (2016) Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy-a multi-institutional observational study. Int J Radiat Oncol Biol Phys 96:1046–1053. https://doi.org/10.1016/j.ijrobp.2016.08.043CrossRefPubMed

Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW et al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399(10338):1886–1901. https://doi.org/10.1016/S0140-6736(21)01790-6CrossRefPubMedPubMedCentral

Qi X, Li H-Z, Gao X-S, Qin S-B, Zhang M, Li X-M et al (2020) Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial. Int J Radiat Oncol Biol Phys 106:282–290. https://doi.org/10.1016/j.ijrobp.2019.09.047CrossRefPubMed

Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G et al (2020) Assessment of postprostatectomy radiotherapy as adjuvant or salvage therapy in patients with prostate cancer: a systematic review. JAMA Oncol 6(11):1793–1800. https://doi.org/10.1001/jamaoncol.2020.2832CrossRefPubMed

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21(10):1341–1352. https://doi.org/10.1016/S1470-2045(20)30454-X. (PMID: 33002438)CrossRefPubMed

Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H et al (2023) Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence—results of a retrospective study. Radiother Oncol. https://doi.org/10.1016/j.radonc.2023.109678CrossRefPubMed

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428. https://doi.org/10.1056/NEJMoa1607529CrossRefPubMedPubMedCentral

Swanson GP, Du F, Michalek JE, Hermans M (2011) Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen. Int J Radiat Oncol Biol Phys 80:62–68. https://doi.org/10.1016/j.ijrobp.2010.01.043CrossRefPubMed

Titel: Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy
verfasst von: Gregory P. Swanson
Kendall Hammonds
Sameer Jhavar
Publikationsdatum: 22.07.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 14/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05085-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy

Abstract

Background and purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2023

Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial

Implementation and update of guideline-derived quality indicators for cervical cancer in gynecological cancer centers certified by the German Cancer Society (DKG)

Cancer outpatients during the COVID-19 pandemic: what Oncoral has to teach us about medical drug use and the perception of telemedicine

Nomograms constructed for predicting diagnosis and prognosis in cervical cancer patients with second primary malignancies: a SEER database analysis

Identifying immune infiltration by deep learning to assess the prognosis of patients with hepatocellular carcinoma

Multi-omics analysis of expression profile and prognostic values of connexin family in LUAD

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie